Cyrus Harmon, Director at Olema Pharmaceuticals, Inc. (OLMA), sold 35,000 shares at $9.36 ($373K) on 2023-08-31, disclosed to the SEC on 2023-09-05.
Scheduled sale ($373k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.36 | 15,000 | $140K | 37.7% |
| 2 | $11.62 | 10,000 | $116K | 31.2% |
| 3 | $11.62 | 10,000 | $116K | 31.2% |
| Total | $10.65 avg | 35,000 | $373K | 100% |
| Filing → |
| OLMA | SELL | 2026-01-16 | $102K | — | Filing → |
| OLMA | SELL | 2025-12-29 | $164K | — | Filing → |
| OLMA | SELL | 2025-09-18 | $285K | — | Filing → |